Breaking News

Financial Report: Merck 3Q

October 26, 2012

Key products help offset August Singulair patent expiry

Merck

3Q Revenues: $11.5 billion (-4%)
 
3Q Earnings: $1.8 billion (+2%)
 
YTD Revenues: $35.5 billion (-1%)
 
YTD Earnings: $5.4 billion (+10%)
 
Comments: Pharmaceutical sales were down 5% to $9.9 billion, including a 5% negative impact from foreign exchange and the loss of market exclusivity for Singulair in the U.S. in August (-55% to $602 million). Januvia sales were up 15% to $975 million. Zetia sales were up 5% to $645 million. Gardasil sales were up 31% to $581 million. Janumet and Isentress sales were up 16% to $405 and $399 million, respectively. Combined sales of Remicade and Simponi declined 9% to $576 million in the quarter. Animal Health sales were down 1% to $815 million. Consumer Care revenues were up 7% to $451 million.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks